Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors

Human Pathology

Volumn 39, Issue 3, 2008, Pages 444-451

  Sun, Baocun ^a   Qie, Shuo ^a   Zhang, Shiwu ^a   Sun, Tao ^a   Zhao, Xiulan ^a   Gao, Songyuan ^a   Ni, Chunsheng ^a   Wang, Xinghui ^a   Liu, Yanxue ^a   Zhang, Lihua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Gastrointestinal stromal tumors; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Microvessel density; VM

Indexed keywords

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MITOSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR BLEEDING; TUMOR VOLUME; ZYMOGRAPHY;

ANTIGENS, CD31; ANTIGENS, CD34; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38749147703     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.07.018     Document Type: Article

References (30)

1. Miettinen M., and Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54 (2003) 3-24
2. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
3. Kikuchi H., Yamashita K., Kawabata T., et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: Sequential analyses. Cancer Sci 97 (2006) 127-132
4. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155 (1999) 739-752
5. Sood A.K., Seftor E.A., Fletcher M.S., et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 158 (2001) 1279-1288
6. Liu C., Huang H., Donate F., et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62 (2002) 5470-5475
7. Shirakawa K., Tsuda H., Heike Y., et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61 (2001) 445-451
8. Sun B., Zhang S., Zhang D., et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16 (2006) 693-698
9. Sun B., Zhang S., Zhang D., et al. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 25 (2004) 1609-1614
10. van der Schaft D.W., Hillen F., Pauwels P., et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65 (2005) 11520-11528
11. Folberg R., and Maniotis A.J. Vasculogenic mimicry. APMIS 112 (2004) 508-525
12. Folgueras A.R., Pendas A.M., Sanchez L.M., and Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48 (2004) 411-424
13. Seftor R.E., Seftor E.A., Koshikawa N., et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metallo-proteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61 (2001) 6322-6327
14. Seftor R.E., Seftor E.A., Kirschmann D.A., and Hendrix M.J. Targeting the tumor micro-environment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1 (2002) 1173-1179
15. Hess A.R., Seftor E.A., Seftor R.E., and Hendrix M.J. Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63 (2003) 4757-4762
16. Seftor E.A., Meltzer P.S., Kirschmann D.A., Margaryan N.V., Seftor R.E., and Hendrix M.J. The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10 (2006) 174-196
17. Kaneyoshi T., Nakatsukasa H., Higashi T., et al. Actual invasive potential of human hepatocellular carcinoma revealed by in situ gelatin zymography. Clin Cancer Res 7 (2001) 4027-4032
18. Qian Z., Ha Y.D., Dong L., and Li N. Ultrastructural observation of gastrointestinal stromal tumors (Chi). J Chin Electr Microsc Soc 19 (2000) 189-190
19. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
20. Hendrix M.J., Seftor E.A., Kirschmann D.A., and Seftor R.E. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res 2 (2000) 417-422
21. Seftor E.A., Meltzer P.S., Schatteman G.C., et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44 (2002) 17-27
22. Allander S.V., Nupponen N.N., Ringner M., et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Canccer Res 61 (2001) 8624-8628
23. Antonescu C.R., Viale A., Sarran L., et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10 (2004) 3282-3290
24. Takahashi R., Tanaka S., Kitadai Y., et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64 (2003) 266-274
25. Beaudry P., Force J., Naumov G.N., et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 11 (2005) 3514-3522
26. Hess A.R., Seftor E.A., Gardner L.M., et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61 (2001) 3250-3255
27. Hendrix M.J., Seftor E.A., Meltzer P.S., et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98 (2001) 8018-8023
28. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 (2003) 411-421
29. Hess A.R., Seftor E.A., Gruman L.M., Kinch M.S., Seftor R.E., and Hendrix M.J. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway. Implications for vasculogenic mimicry. Cancer Biol Ther 5 (2006) 228-233
30. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25